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cholecystokinin (CCK) or calretinin (CR) (Kawaguchi and Kubota, 
1997). CCK and CR both overlap with vasointestinal polypeptide 
(VIP), but VIP does not overlap with PV or SST. Thus PV, SST, and 
VIP can also be used to deﬁ  ne three largely non-  overlapping cell 
groups. In mice, unlike rats, many CR expressing cells also express 
SST (Xu et al., 2006). Nevertheless, as in rats, three non-overlapping 
groups can be distinguished by PV, SST and VIP.
Recombinant adeno-associated virus and lentivirus are prom-
ising vectors for gene therapy because they can infect postmitotic 
neurons and mediate stable gene expression with minimal tox-
icity (Monahan and Samulski, 2000; Galimi and Verma, 2002). 
In addition, genetic methods for selective neuronal tracing or 
inactivation, for which viruses are the best delivery vehicles, have 
been developed to directly study particular cells, but the utility of 
these genetic tools requires the ability to selectively target gene 
expression to speciﬁ  c cell-types (Callaway, 2005; Luo et al., 2008). 
One such way is to use short cis-regulatory sequences (termed 
promoters), which can regulate gene expression using enhanc-
ers, silencers, and/or insulator/boundary elements. We used both 
rAAV2/1 (AAV2 backbone packaged with AAV1 capsid) (AAV) 
and VSV (vesicular stomatitis virus)-G-pseudotyped LV (LV) 
vectors for testing the activity and speciﬁ  city of promoters. AAV 
can package DNA sequences up to ∼5 kilobases (kb) (Dong et al., 
INTRODUCTION
The mammalian cerebral cortex contains two major classes of 
neurons, excitatory and inhibitory. Distinguished from excitatory 
neurons by their primary neurotransmitter, γ-aminobutyric acid 
(GABA) rather than glutamate, inhibitory neurons make up a mod-
est 10–20% of cortical neurons, yet play critical roles in modulating 
the activity of cortical circuits.
Cortical circuits consist of precise cell-type speciﬁ  c connections, 
whereby subcortical brain structures form connections with spe-
ciﬁ  c cortical inhibitory neuron subtypes (Freund and Gulyas, 1991; 
Hornung and Celio, 1992; Gibson et al., 1999). Inhibitory neurons 
also form selective inter-cortical connections to excitatory neurons 
and other inhibitory neurons (Somogyi, 1977; Meskenaite, 1997; 
Tamas et al., 1998; Defelipe et al., 1999; Gonchar and Burkhalter, 
1999). Inhibitory neuron subtypes can be distinguished by mor-
phology, intrinsic physiological properties and cellular function, 
and many can be uniquely differentiated by their gene expression 
proﬁ  les (Peters and Regidor, 1981; Kawaguchi, 1993; Kawaguchi and 
Kubota, 1996, 1997; Cauli et al., 1997; Gonchar and Burkhalter, 1997; 
Thomson and Deuchars, 1997; Parra et al., 1998; Gupta et al., 2000; 
Karube et al., 2004; Xu et al., 2006). Inhibitory neurons in rat can 
be divided into four largely non-overlapping groups, distinguished 
by the expression of either parvalbumin (PV), somatostatin (SST), 
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1996) while LV can accommodate larger sequences up to ∼9 kb 
(Kumar et al., 2001). In the absence of helper virus or genoto-
xic stimuli, rAAV can either integrate randomly or form circular 
episomal provirus by intermolecular concatamerization (Duan 
et al., 1998; Yang et al., 1999). In contrast, LV mediates stable 
transduction by genome integration (Naldini et al., 1996a), cre-
ating the possibility that the same promoter and transgene will 
function differently in the two viruses. An additional difference 
between AAV and LV is viral tropism. We previously reported that 
rAAV2/1 transduces cortical inhibitory neurons more efﬁ  ciently 
than excitatory neurons, while VSV-G-LV transduces excitatory 
neurons more efﬁ  ciently than inhibitory neurons (Nathanson 
et al., 2009). Both AAV and LV also transduce glia. Therefore, 
AAV presumably provides a better system to test for differential 
expression amongst inhibitory neuron subtypes, while LV pro-
vides an alternative platform, and might be advantageous for 
determining whether a promoter drives expression in excitatory 
neurons. AAV and/or LV were used to test promoters derived from 
Takifugu rubripes (fugu), mouse, human and composite regula-
tory element sequences. We sought to create viruses with cell-
type speciﬁ  c promoters capable of driving expression in speciﬁ  c 
inhibitory neurons types, particularly the non-overlapping classes 
expressing either PV, SST or VIP.
With one-eighth the size of the human genome, an average 
gene density of one gene locus per 10.9 kb of genomic sequence 
and a similar repertoire of genes (Aparicio et al., 2002) the fugu 
genome provides an excellent collection of concise DNA regula-
tory regions. The intergenic regions, which are thought to contain 
the bulk of the gene regulatory information, are small and on the 
same scale as the capacities of AAV and LV. We hypothesized that 
for some fugu genes, the mere upstream intergenic region may 
contain genetic regulatory information nearly equivalent to that 
found in the much larger mammalian sequences, and could be 
used for controlling gene expression in the mammalian nervous 
system. Indeed, regulatory regions from the fugu isotocin and 
vasotocin genes drive speciﬁ  c expression in the corresponding 
oxytocin and vasotocin cells in the hypothalamus of transgenic 
rats and mice (Venkatesh et al., 1997; Gilligan et al., 2003). Also, 
a 6.5-kb fragment of the fugu rhodopsin gene produced spe-
ciﬁ  c expression in the retina of transgenic mice (Zhang et al., 
2003). Further analysis also revealed a 500-bp fragment capable 
of driving rod cell speciﬁ  c expression. Therefore, gene regulatory 
sequences speciﬁ  c for cell-types in the nervous system can be 
conserved across the large evolutionary distances between fugu 
and mammals.
The premise of our fugu hypothesis is that distinct subtypes 
of inhibitory neurons in the fugu telencephalon contain simi-
lar proteins and neuropeptides as in mammals, and that their 
expression may be similarly regulated. Telencephalic inhibitory 
neurons in mammals and teleosts, of which fugu is a member, 
and even the ancient sea lamprey, originate in the ganglionic 
eminences of the subpallial telencephalon (Melendez-Ferro et al., 
2002). Therefore, even though ﬁ  sh lack a cortex, the telencephalic 
origin of the mammalian cortical inhibitory neurons is shared 
with ﬁ  sh. As evidence of this link, a reporter construct driven by 
the zebraﬁ  sh distal-less homeobox enhancer DLX4/6, which is 
involved in the generation of inhibitory neurons in the ganglionic 
eminence, drove expression in cells that became mouse cortical 
inhibitory neurons (Stuhmer et al., 2002). Regulatory mecha-
nisms responsible for the generation of inhibitory neurons are 
thus shared between ﬁ  sh and mammals. Importantly, the ﬁ  sh 
telencephalon expresses many of the same inhibitory genes for 
which we intend to test promoters – PV (Brinon et al., 1994), 
CR (Diaz-Regueira and Anadon, 2000; Castro et al., 2003), SST 
(Batten et al., 1990; Becerra et al., 1995) and NPY (Becerra et al., 
1995; Castro et al., 1999).
We tested putative regulatory regions from fugu genes ortholo-
gous to mammalian inhibitory neuron speciﬁ  c markers PV, CR, 
SST and NPY. Additional candidate sequences for these cell-types 
were chosen from genes putatively coexpressed with these inhibi-
tory cell-types in mouse. Sugino et al. (2006) used microarrays 
to proﬁ  le gene expression in several inhibitory neuron subtypes. 
These coexpressed genes provided additional candidates for target-
ing inhibitory neuron subtypes. Motivated by this data, we chose the 
fugu genes titin-cap (TCAP) and secreted frizzled-related protein 2 
(SFRP2), which respectively express in PV and SST cell-types in the 
mouse. In addition to the promoters targeting inhibitory neuron 
populations, we created a fugu promoter for α-calcium/calmodu-
lin-dependent protein kinase II (CAMK), a gene with expression 
restricted to excitatory neurons in the neocortex and hippocampus 
in rat (Liu and Jones, 1996) and monkey (Jones et al., 1994).
Since coexpressed genes may also be coregulated (Kielbase 
et al., 2004; Cora et al., 2005), Sugino et al.’s (2006) data provides 
a resource which we also used to apply bioinformatics analysis 
to suggest regulatory modules responsible for neuronal cell-type 
speciﬁ  c expression in mammals. First, we searched for transcrip-
tion factor binding sites (TFBSs) conserved across coexpressed 
genes and across species. Distinctive TFBSs abundant in regulatory 
regions of genes coexpressed in a cell-type were hypothesized to 
be important for conferring cell-type speciﬁ  c expression. We chose 
human candidate genes containing regulatory sequences exhibit-
ing a maximum number of TFBSs enriched in one cell-type, and 
a minimum number of TFBSs found in genes expressed by the 
other cell-types. Next, human promoter sequence segments were 
identiﬁ  ed and cloned to putatively target SST, PV or VIP expressing 
inhibitory neuron subtypes.
Lastly, we tested promoters consisting of synthetic composite 
regulatory elements (CREs) consisting of TFBSs assembled with 
a minimal promoter. CREs consisting of more than one tran-
scription factor binding site can drive highly speciﬁ  c patterns 
of gene regulation (Kel et al., 1995; Kel-Margoulis et al., 2002). 
These factor-factor interactions have been shown to be synergistic 
or antagonistic. Synergistic   interactions can be a result of coop-
erative binding (Moreno et al., 1995; Brass et al., 1996; Butscher 
et al., 1998; Muhlethaler-Mottet et al., 1998; Okuno et al., 2001) 
or hierarchical loading (Linhoff et al., 1997). Antagonistic inter-
actions can be a result of mutually exclusive binding because of 
competition for overlapping binding sites (Casolaro et al., 1995; 
Klein-Hessling et al., 1996; Takeuchi et al., 1998) or by repressor 
masking an activation domain (Diamond et al., 1990). We created 
CREs by combining DR1 (Okuno et al., 2001) or E1.1 (Scardigli 
et al., 2003) motifs with a neuron restrictive silencing element 
(NRSE) (Bessis et al., 1997; Millecamps et al., 1999) and a minimal 
cytomegalovirus (mCMV) promoter.Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  3
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  8. fSFRP2 (AAV) – secreted frizzled-related protein 2, 1218-bp, 
Fugu 2002 assembly: chrUn:13,504,648-13,505,865 (UCSC), 
upstream of Ensembl transcript SINFRUT00000138275 
(SFRP2). Fugu 2004 assembly: chrUn:96,858,434-96,859,651 
(UCSC), part of ﬁ   rst intron of Ensembl transcript 
ENSTRUT00000017303 (SFRP2).
 9. fSST (AAV) – somatostatin, 2597-bp, Fugu Assembly 2002: 
chrUn:228,946,036-228,948,614 (UCSC), upstream of Ensembl 
transcript SINFRUT00000151429 (SST). Fugu Assembly 
2004: chrUn:232,110,513-232,113,091 (UCSC), downstream 
region of Ensembl transcript ENSTRUT00000025350 (SST).
10. fSST (LV) – 4406-bp A similar, but larger region of fSST 
(AAV). Fugu 2002 assembly: mapped to chrUn:228,946,036-
228,950,367 (UCSC). Fugu 2004 assembly: mapped to 
chrUn:232,108,687-232,113,091 (UCSC).
11. fTCAP (AAV) – titin cap, 2656-bp, Fugu 2002 assembly: 
chrUn:17,827,063-17,829,718 (UCSC), upstream of Ensembl 
transcript SINFRUT00000161814. Fugu 2004 assembly: 
chrUn:49,879,491-49,882,146 (UCSC), upstream of Ensembl 
transcript ENSTRUT00000041782 (TCAP).
DESIGN OF MAMMALIAN REPORTER CONSTRUCTS
Cortical gene expression data (Sugino et al., 2006) were analyzed 
for the excitatory CT6 and YFPH cell-types and for the three inhibi-
tory G30, GIN, and G42 cell-types. Genes with more than a 3-fold 
enrichment compared to any other cell-type were considered can-
didate coexpressed genes. The inhibitory cell-types were generally 
classiﬁ  ed by the designation of one of their member genes: G30-
VIP, G42-PV (note: PV not actually restricted to only this group, 
since it was also expressed in the excitatory neuron population 
YFPH), GIN-SST.
We analyzed the promoters of human genes speciﬁ  c to these 
cell-types to see if we could ﬁ  nd a sequence segment that would give 
cell-type speciﬁ  c expression. To this end, we considered upstream 
segments of the candidate coexpressed genes, including multiple 
sequences for each gene if multiple alternate start sites existed. 
Some of the genes from the microarray analysis did not appear to 
be cell-type speciﬁ  c by in situ hybridization according to the Allen 
Mouse Brain Atlas (Lein et al., 2007). Genes that were not likely 
restricted to inhibitory neurons were discarded, leaving 25 genes 
for G30-VIP, 16 genes for G42-PV and 12 genes for GIN-SST (see 
Table S1 in Supplementary Material).
In order to enhance the probability of isolating a 3-kb seg-
ment from these promoters that would provide cell-type speciﬁ  c 
expression, we subjected the sequences to computational analysis. 
We applied a phylogenetic footprinting approach (Zhang and 
Gerstein, 2003), coupled with TRANSFAC matrices (Matys et al., 
2003) to predict putative TFBS. Each human promoter sequence 
was used to gather orthologous upstream regions from 16 verte-
brate species using the UCSC Genome Browser Database (Kent 
et al., 2002; Karolchik et al., 2008), and a multi-species  promoter 
alignment was assembled with DIALIGN (Morgenstern, 1999). 
Each sequence was then searched against all vertebrate TRANSFAC 
matrices using MATCH (Kel et al., 2003) with the “minSUM” 
score cutoff, which seeks to minimize the sum of both false posi-
tive and false negative matches. Putative TFBS were then mapped 
back to the alignment and used to determine conservation   levels 
MATERIALS AND METHODS
DESIGN OF FUGU REPORTER CONSTRUCTS
Putative fugu gene orthologs were found by tblastn search and 
gene annotation of the following databases : Fugu rubripes v3.0 
or v4.0 genome at JGI1, Queen Mary University of London2 
and Ensembl3. In case of genes duplicated in the ﬁ  sh genome, a 
  putative fugu orthologous gene was chosen based on preserva-
tion of order among short range neighboring genes and DNA 
sequence conservation. When this was compatible with the virus 
DNA capacity, the entire fugu upstream intergenic region was 
introduced into the viral expression vector. When the genomic 
sequence exceeded the capacity of the viral expression vector, 
the maximal upstream sequence proximal to the gene 5′ end was 
chosen. Sequences were isolated from the fugu genomic DNA by 
PCR ampliﬁ  cation using primers ﬂ  anked with restriction enzyme 
cloning sites.
Sequences for the fugu viral vectors were as follows.
 1. fCAMK (AAV) – α-calcium/calmodulin-dependent protein 
kinase II, 2567-bp, Fugu 2002 assembly: chrUn:257,733,699-
257,736,265 (UCSC), upstream of Ensembl transcript 
SINFRUT00000157719 (CAMK). Fugu 2004 assembly: 
chrUn:114,469,050-114,471,616 (UCSC), upstream of 
Ensembl transcript ENSTRUT00000018600 (CAMK).
 2.  fCR (AAV) – calretinin, 2595-bp, Fugu 2002 assembly: 
chrUn:239,797,309-239,799,903 (UCSC), upstream of 
Ensembl transcript SINFRUT00000150025. Fugu 2004 
assembly: chrUn:47,433,038-47,435,619 (UCSC), upstream 
of Ensembl transcript ENSTRUT00000046308 (CR).
 3. fCR (LV) – 6326-bp, A similar, but larger region of fCR 
(AAV). Fugu 2002 assembly: mapped to chrUn:239,793,595-
239,799,905 (UCSC). Fugu 2004 assembly: mapped to 
chrUn:47,429,323-47,435,621 (UCSC).
  4. fNPY (AAV) – neuropeptide Y, 2605-bp, Fugu 2002 assembly: 
chrUn:103,680,529-103,683,131 (UCSC), upstream of  En-
sembl transcript SINFRUT00000153449 (NPY). Fugu2004 
assembly: chrUn:287,512,332-287,514,956 (UCSC), upstream 
of Ensembl transcript ENSTRUT00000016839 (NPY).
 5. fNPY (LV) – 6443-bp A similar, but larger region of fNPY 
(AAV). Fugu 2002 assembly: mapped to chrUn:103,680,529-
103,686,955 (UCSC). Fugu 2004 assembly: mapped to 
chrUn:287,509,165-287,514,956 (UCSC). 
 6.  fPV (AAV) – parvalbumin, 2395-bp, Fugu 2002 assem-
bly: chrUn:103,113,651-103,116,040 (UCSC), upstream of 
Ensembl transcript SINFRUT00000151321 (PV). Fugu 2004 
assembly: chrUn:316,053,780-316,056,172, but is no longer 
identiﬁ  ed as the fugu ortholog. The new fugu ortholog is 
Ensembl transcript ENSTRUT00000000079.
 7. fPV (LV) – 2893-bp A similar, but larger region of fPV 
(AAV). Fugu 2002 assembly: mapped to chrUn:103,113,151-




3http://www.ensembl.orgFrontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  4
Nathanson et al.  Short promoters targeting inhibitory neurons
for the putative TFBS seen in human (these were considered “con-
served” if they were also present in >35% of non-primate mam-
mals in the alignment at the identical location). Presence/absence 
of conserved putative human TFBS were then collected for each 
promoter and compared between cell types. To avoid biasing TFBS 
representation for genes with multiple alternative start sites, this 
initial analysis was done by combining all of the alternative start 
site sequences for each gene (i.e. each gene promoter was only 
counted once).
We sought to identify TFBSs characteristic of each group of 
genes distinctive to each cell-type, and to find the promoters 
that had a maximum number of sites for this cell-type and a 
minimum number of sites for TFBSs characteristic of other cell-
types. The analysis did not identify any TFBS enriched in most 
promoters of one gene group and completely absent in promot-
ers of other groups. However, we did find sites that were clearly 
overrepresented in each of the three groups of coexpressed genes 
(see Tables S2–4 in Supplementary Material). Distinctive TFBS 
for each cell type were defined as those conserved in at least 
10% of promoters from that cell type, and enriched relative to 
the other two cell types by a ratio of >1.5 (or enriched relative 
to one cell type by a ratio of >2 and the other by a ratio of >1.2, 
to allow for sites that were particularly distinctive for only one 
of the other cell types). We next determined which genes had 
promoters which maximized TFBSs distinctive for one cell-type 
and minimized TFBSs distinctive for other cell-types. We also 
selected the optimal alternative start site promoter in genes 
which had multiple start sites. In almost all cases, the optimal 
promoter fragment was the one that appeared to be immedi-
ately proximal to the coding region of the primary isoform of 
the gene.
Sequences for the mammalian viral vectors were as follows. 
Sequences 6–12 were chosen based on the computational analysis 
described above. Sequences 1–5 were chosen based on previous 
publications or other bioinformatic analyses.
 1.  hSyn (AAV) – synapsin I, 468-bp, Human 2006 assembly: 
chrX:47,364,154-47,364,622 (UCSC) (Kugler et al., 2003).
  2.  mGAD2 (LV) – glutamate decarboxylase 2, 4415-bp, Mouse 
2007 assembly: chr2:22,473,768-22,478,182 (UCSC).
  3. mA93 (AAV) – riken gene A930038C07Rik, 2694-bp. 
Consists of two conserved regions, which we concatena-
ted. Mouse 2007 assembly: chr6:65,592,490-65,594,288 and 
chr6:65,620,737-65,621,604 (UCSC).
  4.  mSST (LV) – somatostatin, 6001-bp, Mouse 2007 assembly: 
chr16:23,890,831-23,896,831 (UCSC).
 5.  hPDGFRA (AAV) – platelet derived growth factor receptor 
alpha, 2650-bp, Human 2006 assembly: chr4:54,787,691-
54,790,341 (UCSC).
  6.  hGRM1 (AAV) – glutamate receptor, metabotropic 1, 2585-
bp, Human 2006 assembly: chr6:146,389,761-146,392,345 
(UCSC).
  7.  hNPPC (AAV) – c-type natriuretic peptide precursor, 2585-
bp, Human 2006 assembly: chr2:232,499,151-232,501,735 
(UCSC).
 8. hADM (AAV) – adrenomedullin, 2555-bp, Human 2006 
assembly: chr11:10,281,564-10,284,118 (UCSC).
  9.  hST3GAL6 (AAV) – type 2 lactosamine alpha-2,3-sialyltran-
sferase, 2739-bp, Human 2006 assembly: chr3:99,931,562-
99,934,300 (UCSC).
10.  hRREB1 (AAV) – ras responsive element binding protein 1, 
2715-bp, Human 2006 assembly: chr6:7,050,563-7,053,277 
(UCSC).
11.  hDIO2 (AAV) – deiodinase, iodothyronine, type II, 2568-
bp, Human 2006 assembly: chr14:79,747,568-79,750,140 
(UCSC).
12.  hNR2F2 (AAV) – nuclear receptor subfamily 2, group F, mem-
ber 2, 2568-bp, Human 2006 assembly: chr15:94,667,976-
94,670,543 (UCSC).
DESIGN OF COMPOSITE REGULATORY ELEMENT (CRE) REPORTER 
CONSTRUCTS
Three CREs were constructed. Elements were ordered as oligonu-
cleotides, and assembled as a DNA cassette.
1.  E1.1-mCMV (AAV) – four E.1.1 binding sites (5′TCATTCAC
GCCTAGAAGCAG3′), as described in Scardigli et al. (2003), 
were assembled upstream of a minimal CMV promoter con-
sisting of 58 base pairs near the 3′ end of the CMV promoter. 
The distance between the 3′ most E1.1 site TAGGCGTGTAC
GGTGGGAGGTCTATATAAGCAGAGCTGGTTTAGTGAAC
CGTCAGATC and the mCMV was 59 bp. This cassette was 
cloned into the AAV transfer vector. (AAV-E1.1)
2.  E1.1-NRSE-mCMV (AAV) – the E1.1-mCMV construct plus 
a neuron restrictive silencing element (NRSE) binding site 
(5′TTCAGCACCACGGACAGCGCC3′) inserted between 
the E1.1 sites and the mCMV. The distance between the 3′ 
most E1.1 site and NRSE was 61 bp, and between NRSE and 
mCMV was 3 bp. This construct was cloned into the AAV 
transfer vector. (AAV-E1.1-NRSE)
3.  NRSE-DR1-mCMV (AAV) – a single DR1 binding site (5′T
CTAGGGGTCAAAGGTCACCGG3′), as described in Okuno 
et al. (2001), was inserted between an upstream NRSE bin-
ding site (5′TTCAGCACCACGGACAGCGCC3′) and down-
stream of a minimal CMV promoter. The distance between 
NRSE and DR1 was 9 bp, and between DR1 and mCMV was 
12 bp. This construct was cloned into the AAV transfer vector. 
(AAV-DR1-NRSE)
VIRUS PRODUCTION
Promoters were cloned into either ITR ﬂ  anked AAV transfer vectors 
(Kaspar et al., 2002) or LV transfer vectors (pCSC-SP-PW, Marr 
et al., 2004) expressing green ﬂ  uorescent protein (GFP) or red 
ﬂ  uorescent protein DsRed-Express (RFP). Plasmids were puriﬁ  ed 
using endotoxin-free maxiprep kits (Qiagen, Valencia, CA, USA). 
Recombinant rAAV2/1 (AAV2 backbone packaged with AAV1 cap-
sid) was produced by BBS/CaCl2 or PEI mediated co-transfection 
of 293T cells with the AAV2 ITR ﬂ  anked transfer vector, pXR1 (AAV 
type-1) and pXX6-80 (Ad5 genome) (Rabinowitz et al., 2002). Cells 
were harvested and lysed, treated with   benzonase (Sigma-Aldrich 
D9542, St. Louis, MO, USA), and virus was concentrated and 
 puriﬁ  ed by iodixanol gradient centrifugation (Zolotukhin et al., 
1999). Lentivirus was produced by HBS/CaCl2 mediated co-trans-
fection of 293T cells with the LV transfer vector and   plasmids Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  5
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pMDL, pRev, and pVSVG (Naldini et al., 1996b). Media was col-
lected and virus concentrated through multiple centrifugation steps 
(Tiscornia et al., 2006).
VIRUS TITRATION
Viral genomes were quantiﬁ  ed using SYBR Green with a qPCR 
cycler (ABI 7900HT, Applied Biosystems, Foster City, CA, USA). 
AAV genomic DNA was isolated by lysing AAV in 2 M NaOH 
for 30 min at 56°C, and neutralizing with HCl. LV was incu-
bated with DNase I (NEB, Ipswich, MA, USA), and RNA isolated 
(QIAamp MinElute Virus Spin kit, Qiagen, Valencia, CA, USA), 
followed by reverse transcription (Superscript III kit, Invitrogen, 
Carlsbad, CA, USA). Viral DNA was diluted and compared to a 
standard curve created from a known quantity of transfer vector. 
Infectious titers were determined by infecting conﬂ  uent 293T 
cells with serial dilutions of virus, followed 60 h later by two 
PBS washes, trypsinization, centrifugation to isolate cells, DNA 
isolation by proteinase K digestion in SNET lysis buffer (20 mM 
Tris (pH 8), 1 mM EDTA, 1% SDS, 0.4 M NaCl) at 55°C for 12 h, 
followed by alcohol precipitation. Concentration of the precipi-
tated DNA, composed of cellular and viral DNA, was determined 
by spectrophotometry. qPCR was performed in the same manner 
as used to determine the genomic titer. The titer was normal-
ized by the concentration of precipitated DNA loaded into the 
PCR reaction.
STEREOTAXIC VIRUS INJECTIONS
Adult wild-type ICR mice, wild-type C57BL/6J mice, GAD67-GFP 
(Δneo) knock-in mice (Tamamaki et al., 2003), adult wild-type 
Sprague-Dawley rats, and a ∼4-year old adult monkey (Macaca 
mulatta) were injected with viruses following procedures approved 
by the Salk Institute Animal Care and Use Committee guidelines. 
Animals were anesthetized using a cocktail of ketamine and xyla-
zine, and/or isoﬂ  urane. Virus was delivered via a glass micropi-
pette (∼30–50 µm tip diameter) using air pressure applied via a 
Picospritzer II (General Valve Corporation, Fairﬁ  eld, NJ, USA). 
Stereotaxic injections to mouse somatosensory cortex: 3.0 mm lat-
eral, −0.5 mm to −1.0 mm bregma, at depths of 0.75 and 0.45 mm; 
DG: 1.25 mm lateral, −2.0 mm bregma, at depths of 1.75, 1.45 and 
1.10 mm; thalamus: 1.25 mm lateral, −2.0 mm bregma, at depths 
2.25 and 2.0 mm. Stereotaxic injection to rat somatosensory cor-
tex: 5.0 mm lateral, −2.3 mm bregma, at depths of 2.0, 1.3 and 
0.6 mm. Stereotaxic injections to monkey precentral gyrus (motor 
cortex) and postcentral gyrus (somatosensory cortex) at depths 
of 1.2, 0.8 and 0.4 mm. Five-minute injections at each depth usu-
ally corresponded to 1–2 µl of virus, delivered at 20 psi, with 1 
pulse per   second. The pulse duration was adjusted to modulate 
the ﬂ  ow rate.
HISTOLOGY AND IMMUNOHISTOCHEMISTRY
25–40 µm thick sections cut on a freezing microtome were stained 
with one or more of the following antibodies: Chicken anti-GFP 
(Aves Labs GFP-1020 1:500, Tigard, OR, USA), Rabbit (Rb) 
anti-DsRed (Clontech 632496 1:200, Mountain View, CA, USA), 
Mouse (Ms) anti-NeuN (Millipore MAB377 1:100, Billerica, MA, 
USA), Rb anti-PV28 (Swant), Ms anti-PV (Sigma P3088), Rb 
anti-PV28 (Swant 1:1000), Ms anti-PV (Sigma P3088 1:1000), Rb 
anti-CR (Swant 1:1000), Rb anti-VIP (ImmunoStar 20077 1:500), 
Rb anti-NPY(Chemicon AB1915 1:500), Rat anti-Somatostatin 
(Chemicon MAB354 1:200), and Ms anti-CAMKii (Chemicon 
MAB869 1:500). As secondary antibodies we used one or more of 
Cy2 (Jackson Immuno 1:100, West Grove, PA, USA), AlexaFluor 
568 (Invitrogen A11036 1:100, Carlsbad, CA, USA), RhodX 
(Jackson Immuno 1:100), and Cy5 (Jackson Immuno 1:100) ﬂ  uor-
ophores raised against the appropriate species. Mounted sections 
were counterstained with 10 µM DAPI (Sigma-Aldrich D9542, 
St. Louis, MO, USA) in PBS. Sections were dehydrated through 
xylenes and coverslipped using Krystalon (EMD Chemicals, 
Gibbstown, NJ, USA).
IMAGING AND CELL-COUNTING
Quantitative data described in the results are based on observa-
tions of label from at least 2, but typically 5 sections, from 3 
or more animals (except for AAV-fPV and results from monkey 
which are from a single animal). Except for the AAV-fSST-RFP 
in GAD67-GFP analysis, cells in all cortical layers in each sec-
tion were combined, as the inhibitory neuron subtype variability 
across layers was presumed to be less than the variability between 
sections. For each injection analyzed, tissue sections were scanned 
to identify the region with the highest density of labeling and this 
was considered the center of the injection site. Neurons express-
ing reporter from the injected vector were counted in this section 
and up to eight adjacent sections and scored for no overlap or 
double-label with markers identifying neuron subtypes. The total 
numbers of labeled cells counted and scored varied between sec-
tions and layers due to differences in labeling density for different 
vectors and cell-type antibodies. Typically, ∼10 double-labeled 
cells were counted per section [range: 0–163 (AAV-fNPY tissue 
stained with anti-PV antibody)] for cell-type speciﬁ  c antibody 
labeling, and a total of more than 170 cells for each vector. For 
AAV-fSST-RFP in GAD67-GFP mice, 8 sections with 17–38 cells 
per section were counted.
To count and score labeled cells, ﬂ  uorophores were imaged 
independently at three confocal planes at 10× or 20× magni-
ﬁ  cation using either a Nikon TE300 with a Bio-Rad radiance 
2100 system or an Olympus BX51 with a Bio-Rad Radiance 
2100MP system. Images were projected and merged in RGB 
space. Quantiﬁ  cation of overlap of cell labeling was done using 
the confocal images in Adobe Photoshop. Cortical layers were 
determined by DAPI staining.
RESULTS
To target speciﬁ  c neuron cell-types in mammals, we tested regu-
latory sequences derived from multiple sources: (i) promoter 
sequences derived from putative orthologous fugu genes, (ii) mam-
malian promoter segments from genes putatively co-expressed in 
known inhibitory neuron subtypes, and (iii) assembled composite 
regulatory elements (CREs) containing TFBSs.
We used both AAV and LV as delivery vectors. Most of the 
viruses were tested for speciﬁ  city in mouse somatosensory cortex. 
Some of the viruses were also tested in mouse dentate gyrus or 
thalamus, or in the cortex of rat or monkey. Cell-type speciﬁ  city 
was   determined by cellular morphology and co-localization with Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  6
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inhibitory neuron subtype speciﬁ  c antibodies parvalbumin (PV), 
calretinin (CR), somatostatin (SST), neuropeptide Y (NPY) and/or 
vasoactive intestinal polypeptide (VIP).
FUGU PROMOTERS
Fugu promoters in AAV drove expression in mouse cortex
Fugu 5′ intergenic DNA sequences up to 2.8 kb, including 5′ UTRs, 
were cloned into green ﬂ  uorescent protein (GFP) or red ﬂ  uorescent 
protein DsRed-Express (RFP) reporter vectors (Figure 1). All but 
one of the vectors tested aimed to target inhibitory neurons. The 
exception was the fugu α-calcium/calmodulin-dependent protein 
kinase II (AAV-fCAMK) vector targeting excitatory neurons. All 
fugu promoters tested drove expression in mouse somatosensory 
cortex (Figures 2 and 3, Table 1), but the expression strength varied 
between vectors. AAV expression of fugu somatostatin (AAV-fSST) 
and fugu neuropeptide Y (AAV-fNPY) vectors were widespread 
in all cortical layers with transduction often observed more than 
300 µm from the injection column (Figures 2A,D). Calretinin 
(AAV-fCR), parvalbumin (AAV-fPV), secreted frizzed-related pro-
tein 2 (AAV-fSFRP2), titin-cap (AAV-fTCAP) and AAV-fCAMK 
vectors showed expression usually conﬁ  ned to less than 200 µm 
from the injection site (Figures 2G,J and 3A,D,G). Depending 
on the virus injection, most vectors showed more widespread 
expression in layers 2/3 and 5 (∼500 µm laterally). Many neuron 
types in layers 2/3 and 5 send projections to the brain surface, 
and thus cells far from the injection site are capable of taking 
up virus which often spreads laterally beneath the pia following 
pressure injections.
Examination of the morphologies of cells labeled with AAV-
fSST, AAV-fNPY, AAV-fPV and AAV-fCAMK indicated expression 
was almost entirely restricted to neurons, with no visible glial cell 
expression (Figures 2A–I and 3G–I). AAV-fCR, AAV-fSFRP2 and 
AAV-fTCAP expression was also mostly neuronal, but the presence 
of small, compact transgene labeled cells with bushy   processes 
indicated that promoters were also active in glia (Figures 2J–L 
and 3A–F, glia marked with upward arrows). Pyramidal shaped 
cell bodies and apical dendrites are characteristic traits of cortical 
pyramidal neurons (excitatory neurons). Due to the preservation 
of apical dendrites, pyramidal neuron identiﬁ  cation was best in 
brain sections cut closest to the coronal plane, parallel to the apical 
dendrites. Non-ideal cuts do not show continuous apical dendrite 
label. As predicted, AAV-fCAMK showed many pyramidal cell 
bodies and apical dendrites (Figures 3G–I, pyramidal neurons 
marked with downward arrows). However, injections of AAV-fPV 
and AAV-fTCAP also labeled excitatory neurons (Figures 2G–I 
and 3D–F). The labeled pyramidal cells were typically located in 
layer 5. In contrast, AAV-fSST, AAV-fNPY, AAV-fCR and AAV-
fSFRP2 did not show many cells morphologically identiﬁ  able as 
excitatory (Figures 2A–F,J–L and 3A–C). All promoters, includ-
ing fCAMK (Figures 3G–I), showed scattered non-pyramidal 
cells in all cortical layers consistent with expression in inhibi-
tory neurons.
Taken together these results indicate that only AAV-fSST and 
AAV-fNPY restrict expression to mouse inhibitory interneurons. 
The degree to which promoter speciﬁ  cities and viral tropism con-
tribute to selective inhibitory neuron expression will be considered 
in the context of further results presented below.
Fugu promoters in AAV drove expression in rat and monkey cortex
Injections of AAV-fSST, AAV-fNPY and AAV-fCAMK into rat and 
monkey somatosensory cortex showed robust transgene expression 
that was almost entirely restricted to neurons (Figure 4). As in 
the mouse cortex, morphology of AAV-fSST expressing cells sug-
gested that nearly all of the labeled cells were inhibitory neurons 
(Figures 4A–C). In contrast, the morphology of AAV-fNPY and 
AAV-fCAMK expressing cells in rat and monkey cortex indicated 
expression in both pyramidal and inhibitory cells (Figures 4D–I). 
As predicted, AAV-fCAMK labeled many pyramidal neurons. In 
comparison, AAV-fNPY drove expression in only a few pyramidal 
neurons. Staining AAV-fCAMK sections with CAMK antibody 
FIGURE 1 | Vector design. Transfer vectors for adeno-associated virus 
(AAV) and lentivirus (LV) were constructed as in (A) and (B), respectively. 
The capacity of AAV and LV allowed promoter sequences of approximately 2.8 
and 6.6 kb, respectively. AAV contained either the green ﬂ  uorescent protein 
(GFP) or red ﬂ  uorescent protein DsRed-Express (RFP). Lentivirus contained GFP . 
Components of AAV include: ITR – AAV2 inverted terminal repeat, SD/SA – 
splice donor splice acceptor intronic element (human beta globin), XFP –either 
GFP or RFP , BGH – poly(A). Components of LV include: LTR – long terminal 
repeat, Psi – element for viral genome packaging, RRE – Rev response 
element, cPPT – central polypurine tract, WPRE – woodchuck hepatitis virus 
posttranscriptional regulatory element, U3PPT – upstream border of the 3´ long 
terminal repeat polypurine tract. Viruses were made as described in Tables 1–3.Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  7
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FIGURE 2 | Fugu promoters in AAV expressed in mouse cortex. Fugu 
promoters in AAV injected in mouse somatosensory cortex expressed GFP . 
Wide-angle images in the left column (A,D,G,J) show multilayer viral expression 
patterns. Close-up images centered on layer 5 and layer 2/3 are shown in the 
middle column (B,E,H,K) and right column (C,F,I,L), respectively. Expression of 
fugu promoters in AAV are shown in rows: somatostatin [AAV-fSST,
(A–C)], neuropeptide Y [AAV-fNPY, (D–F)], parvalbumin [AAV-fPV, (G–I)], and 
calretinin [AAV-fCR, (J–L)]. Upward arrows mark glia and downward arrows 
mark excitatory pyramidal neurons. Dorsal (D) and lateral (L) directions for all 
images are as indicated in (L). Scale bars are 50 µm.Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  8
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conﬁ  rmed some of the AAV-fCAMK labeled cells were excitatory. 
However, staining of each of these viruses with inhibitory neuron 
antibody markers NPY, CR and SST conﬁ  rmed that at least some 
of the labeled cells from each virus, including AAV-fCAMK, were 
inhibitory. Therefore, while AAV-fCAMK drove expression in large 
numbers of excitatory neurons, this vector does not restrict expres-
sion to excitatory neurons, and may not be as selective as the mouse 
CAMK promoter version previously characterized in a lentiviral 
expression vector (Dittgen et al., 2004; Nathanson et al., 2009). 
Together with the mouse results, we observed that in rodents, of 
all the fugu promoters tested, only AAV-fSST restricted expression 
to inhibitory neurons.
Fugu promoters in AAV drove expression in dentate gyrus (DG) and 
thalamus
We tested the fugu promoters in dentate gyrus of the hippoc-
ampus, which also contains diverse populations of neurons. The 
granule cell layer (GZ) of the DG is composed predominantly 
of excitatory granule cells, while inhibitory neurons are concen-
trated along the inner subgranular lining of the GZ (SGZ) (Patton 
and McNaughton, 1995). In the PoDG, about half of the neurons 
are inhibitory and half of the neurons are excitatory mossy cells 
(Blasco-Ibanez and Freund, 1997), yet some of the mossy cells 
in the PoDG express CR, but are not inhibitory (Blasco-Ibanez 
and Freund, 1997). AAV-fSST almost exclusively labeled cells in 
FIGURE 3 | Fugu promoters in AAV expressed in mouse cortex. Fugu 
promoters in AAV injected in mouse somatosensory cortex expressed GFP . 
Wide-angle images in the left column (A,D,G) show multilayer viral expression 
patterns. Close-up images centered on layer 5 and layer 2/3 are shown in the 
middle column (B,E,H) and right column (C,F,I), respectively. Expression of fugu 
promoters in AAV are shown in rows: secreted frizzled-related protein 2 
[AAV-fSFRP2, (A–C)], titin-cap [AAV-fTCAP , (D–F)] and α-calcium/calmodulin-
dependent protein kinase II [AAV-fCAMK, (G–I)]. Upward arrows mark glia and 
downward arrows mark excitatory pyramidal neurons. Dorsal (D) and lateral (L) 
directions for all images are as indicated in (I). Scale bars are 50 µm.Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  9
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the PoDG and SGZ (Figures 5A,B). AAV-fNPY injections in the 
DG labeled cells in PoDG, SGZ and a few scattered cells in GZ 
(Figures 5C,D). While not quantitative, immunostaining of AAV-
fSST and AAV-fNPY sections with inhibitory markers PV, SST 
and NPY conﬁ  rmed inhibitory labeled cells. Immunostaining, 
together with little or no expression in the GZ, suggested AAV-fSST 
and AAV-fNPY may have biased expression towards inhibitory 
 neurons in mouse DG. In contrast and as predicted, AAV-fCAMK 
drove strong expression both in cells in PoDG and in granule cells 
(Figures 5E,F).
Deeper injections into mouse thalamus with the AAV-fCAMK 
vector revealed semi-restrictive expression to the anteroven-
tral nucleus of the thalamus (Figures 5G,H). Contrary to the 
  activity of AAV-fCAMK, in situ hybridization images from the 
Allen Mouse Brain Atlas (Lein et al., 2007) indicate that CAMK 
expression is weak in the anteroventral nucleus and strong in 
other areas of thalamus.
Since CAMK has also been reported to be speciﬁ  cally expressed 
in the koniocellular layer of primate LGN (Calkins et al., 2005), 
we also injected this vector in monkey LGN. LGN injections, 
however showed that AAV-fCAMK did not restrict expression 
to the   koniocellular neurons (data not shown). This evidence 
  indicated that this vector did not recapitulate the natural expres-
sion patterns of CAMK in the mouse or monkey thalamus.
AAV-fSST expression strongly favored cortical inhibitory neurons
Since AAV-fSST showed the highest level of inhibitory neuron spe-
ciﬁ  c expression, we sought to quantify the degree of selectivity of 
this vector. To this end a new viral vector, AAV-fSST-RFP driving 
RFP rather than GFP, was constructed and injected into the somato-
sensory cortex of the knock-in mouse line GAD67-GFP (Δneo), in 
which GFP was inserted into the glutamate decarboxylase (GAD67) 
locus (Tamamaki et al., 2003) (Figure 6). In these mice, almost all 
of the GFP-positive cells showed GAD67 immunoreactivity in the 
perikarya or neuropil (Tamamaki et al., 2003) Use of these animals 
facilitated identiﬁ  cation of GABAergic neurons without confounds 
related to GAD or GABA staining reliability.
Cortical sections from GAD67-GFP mice injected with 
AAV-fSST-RFP were scored for both GFP and RFP expression. 
Cells expressing both GFP and RFP were considered inhibitory 
(Figure 6C). We observed that 93% ± 7%, 95% ± 11%, 80% ± 13% 
and 89% ± 11% (mean ± standard deviation) of the cells in layers 
Table 1 | AAV and LV vectors with fugu promoters.












Calretinin AAV-fCR GFP 9.70E + 10 2595 Inhibitory neuron 
subtype (CR)
+− +
Neuropeptide Y AAV-fNPY GFP 6.70E + 10 2605 Inhibitory neuron 
subtype (NPY)
− − +++
Somatostatin AAV-fSST GFP 1.40E + 11 2597 Inhibitory neuron 
subtype (SST)
− − +++
RFP 5.92E  + 11 − + +++
Parvalbumin AAV-fPV GFP 1.20E + 11 2395 Inhibitory neuron 
subtype (PV)
−+ + + +
Secreted Frizzled 
Receptor Protein 2
AAV-fSFRP2 GFP 2.70E + 11 1218 Inhibitory neuron 
subtype (SST)
+− +







AAV-fCAMK GFP 4.5E + 10 2567 Excitatory neurons −+ + + +
Calretinin LV-fCR GFP 2.01E + 10 6326 Inhibitory neuron 
subtype (CR)
−+ +
Neuropeptide Y LV-fNPY GFP 4.51E + 10 6443 Inhibitory neuron 
subtype (NPY)
−+ +
Somatostatin LV-fSST GFP 4406 Inhibitory neuron 
subtype (SST)
−+ +
Parvalbumin LV-fPV GFP 3.54E + 10 2893 Inhibitory neuron 
subtype (PV)
−+ + +
(a) Adeno-associated virus (AAV) and lentivirus (LV). Fugu derived sequences are denoted by the preﬁ  x “f” .
(b) Length of the promoter used in the virus (bases).
(c) Scoring is from mouse injections to somatosensory cortex.Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  10
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FIGURE 4 | AAV-fSST, AAV-fNPY and AAV-fCAMK expressed in rat and 
monkey cortex. Viruses expressing GFP were injected in rat somatosensory 
cortex (A,B,D,E,G,H) and monkey (C,F,I) motor or somatosensory cortex. 
Molecular identities of some GFP labeled cells of AAV-fSST (A–C) 
[(C) – motor cortex], AAV-fNPY (D–F) [(F) – motor cortex] and AAV-fCAMK 
(G–I) [(I) – somatosensory cortex] were determined by co-labeling with NPY, 
CR, SST and CAMK antibodies. Antibodies are indicated in their 
representative color. Overlap of green and red is yellow; green and blue is 
purple; green, red and blue is white. Examples of cells consistent with 
pyramidal morphology are marked with arrows. Boxed inserts are at 
2× magniﬁ  cation. Dorsal (D) and lateral (L) directions for all images are as 
indicated in (I). Scale bars are 50 µm.
2/3, 4, 5 and 6 were inhibitory, respectively. To interpret the signiﬁ  -
cance of these percentages, we needed to account for the tropism of 
AAV and the expected chance rate of inhibitory neuron expression. 
Our previous work (Nathanson et al., 2009) showed that with high 
titer rAAV2/1, reporter expression in excitatory and inhibitory 
neurons is proportional to their respective population percentages, 
but that low titer virus reveals a bias towards inhibitory neurons. 
To estimate the expected proportion of excitatory/inhibitory neu-
rons transduced by AAV virus of this titer (9.1 × 109 infectious 
particles/ml) we applied a linear ﬁ  t to transduction ratios from 
AAV-hSYN-RFP (data from Nathanson et al., 2009). The expected 
neurons transduced by the neuronally ubiquitous human  synapsin 
promoter (AAV-hSYN-RFP), are ∼68%, 77%, 50% and 65% inhibi-
tory in layers 2/3, 4, 5 and 6 respectively. These rates reﬂ  ect a 
strong but not exclusive bias toward inhibitory neurons, which 
would have comprised only about 10–20% of the population by 
chance (Nathanson et al., 2009). On average, the fSST promoter 
in AAV preferentially drove expression in ∼40% more inhibitory 
neurons than would be expected from a promoter producing no 
bias; the proportion of inhibitory neurons expressing RFP were 
signiﬁ  cantly higher with fSST in AAV than with the hSyn promoter 
in the same virus and at matched titer (p values of 0.0003, 0.0223, 
0.0060, 0.0595 for layers 2/3, 4, 5 and 6 for a one sample t-test to 
the estimated ratios).Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  11
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FIGURE 5 | Fugu promoters in AAV expressed in mouse dentate gyrus 
(DG) and thalamus. Fugu promoters in AAV drove GFP expression in 
subcortical areas of the DG and thalamus. Virus expression is shown in green 
[AAV-fSST – (A,B); AAV-fNPY – (C,D); AAV-fCAMK – (E–H)]. Subcortical 
anatomical regions – granule cell layer (GZ) and polymorphic layer (PoDG) shown 
in (A–F), are described in (F). The anteroventral nucleus of the thalamus (AV) 
shown in (G) and (H), is described in (H). Cell-type markers PV, SST and NPY are 
shown in red. Green and red overlap is yellow. Boxed inserts are at 2× 
magniﬁ  cation. Dorsal (D) and lateral (L) directions for all images are as indicated 
in (H). Scale bars are 50 µm.Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  12
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FIGURE 6 | AAV-fSST predominately labeled inhibitory neurons in 
mouse cortex. Mouse cortex with inhibitory neurons expressing GFP 
under the control of the GAD67 promoter (A) was injected with AAV-fSST 
expressing RFP (B). Panel (C) is the overlap of the boxed region in 
(A) and (B). Green and red overlap is yellow. Examples of cells with 
green and red overlapping label are indicated by arrows. Dorsal (D) and 
lateral (L) directions for all images are as indicated in (C). Scale bars
 are 50 µm.
Fugu promoters failed to generate inhibitory neuron subtype 
speciﬁ  c expression
The expression of fugu promoters in AAV in inhibitory neuron sub-
types was quantiﬁ  ed in mouse cortex by identifying cells expressing 
GFP from viral vector that were co-labeled with antibodies for CR, 
PV, SST, VIP and NPY. Cell-type speciﬁ  c antibody-labeled cells were 
counted in regions deﬁ  ned by the virus spread. Figure 7 shows 
an example of cell-type antibody and GFP label in mouse cortex 
injected with AAV-fSST (GFP).
Virus expression in each cell-type was quantiﬁ  ed by dividing 
the number of double labeled cells (GFP and cell-type antibody 
label) by the total number of cell-type antibody labeled cells in 
the virus labeled regions. First, to identify a baseline level of trans-
duction of AAV in inhibitory neuron subtypes, expression from 
the human synapsin (hSYN) promoter was quantiﬁ  ed. Even with 
the high titer AAV-hSYN virus (4.9 × 1010 infectious particles/ml) 
(Nathanson et al., 2009), not every inhibitory neuron expressed the 
transgene, presumably because many neurons were not infected. 
In the injected region of mouse somatosensory cortex, AAV-hSYN 
labeled 72%, 79%, 70%, 55% and 97% of CR, PV, SST, VIP and NPY 
cells, respectively (Figure 8). While the numbers of cells were small, 
these numbers suggest that some inhibitory cell-types were trans-
duced more efﬁ  ciently than others. For example, almost all of the 
NPY+ cells, but only about half of the VIP+ cells were labeled.
We observed that AAV-fSST, AAV-fNPY, AAV-fPV and AAV-fCR 
expressed in all identiﬁ  ed inhibitory cell-types, demonstrating that 
none of the promoters restricted expression to a particular inhibitory 
neuron subtype (Figure 8). AAV-fSST and AAV-fNPY promoters did 
not show signiﬁ  cant differences in inhibitory neuron subtype expres-
sion compared to the expression of high titer AAV-hSYN. Interestingly 
however, AAV-fPV and AAV-fCR showed a signiﬁ  cant reduction in 
PV+ and CR+ cells, respectively (t-test – p = 0.001 and p = 0.003), the 
very types of cells that their promoters were aimed to target.
Fugu promoters in lentivirus drove expression in excitatory neurons
In comparison to AAV, a GFP expressing lentivirus (LV) vector can 
accommodate longer promoter sequences up to ∼6.6 kb. Larger 
regions of the fugu PV, CR, SST and NPY promoter sequences, 
encompassing up to the entire 5′ intergenic region were cloned 
into lentivirus driving GFP (Figure 1). We previously found that 
following cortical injections, LV labeled large numbers of excitatory 
neurons and glia, but it did not label large numbers of inhibitory 
neurons (Nathanson et al., 2009). These results suggested that LV 
would provide a skewed, but more sensitive assay than AAV to assess 
the ability of promoters to express in excitatory neurons.
Injection into mouse somatosensory cortex revealed that all fugu 
promoters in LV drove gene expression (Figure 8, Table 1). LV-fPV 
and LV-fSST expression signals were the strongest and LV-fNPY 
and LV-fCR were the weakest (Figure 9). All of these promoters 
in LV appeared to restrict expression to neurons versus glial cells. 
Morphological observations indicated that all fugu promoters in LV 
drove expression in a higher proportion of excitatory cells than they 
did in AAV. In LV-fPV, the labeled cells were densely packed, consist-
ent with large numbers of dense pyramidal neurons (Figures 9A,B). 
Cell label density was more scattered for LV-fSST, but cell density was 
still higher than would be expected if all the cells were inhibitory. 
Consistent with the greater cell density of excitatory neurons, we also 
observed a few cells with pyramidal neuron morphology (Figures 
9C,D). Expression of LV-fNPY and LV-fCR vectors was restricted 
to only a handful of cells (Figures 9E,F). In contrast to AAV-fCR, 
LV-fCR did not label any glia. Co-label with inhibitory markers PV, 
CR, SST, and VIP indicated that at least a few cells labeled by each 
virus were inhibitory (data not shown). Promoter activity in LV 
was largely in agreement with the promoter activity in AAV, but LV 
expression shifted toward excitatory expression consistent with the 
expected differences due to viral tropism (Nathanson et al., 2009).
MAMMALIAN PROMOTERS
Promoter sequences were isolated from mouse and human DNA 
sequences for genes associated with known cell-types (Table 2). Preﬁ  xes 
denote mouse (m) and human (h) derived promoter sequences. The 
promoters of mouse glutamate decarboxylase 2   targeting all inhibi-
tory neurons (LV-mGAD2) and mouse somatostatin (LV-mSST) 
were cloned into the LV vector. We also constructed GFP or RFP 
expressing AAV vectors with the promoters of platelet-derived growth 
factor receptor, alpha polypeptide (AAV-hPDGFRA) – targeting Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  13
Nathanson et al.  Short promoters targeting inhibitory neurons
FIGURE 7 | AAV-fSST expression co-labeled with CR, PV, SST, VIP and NPY 
antibodies. AAV-fSST-GFP expression in mouse somatosensory cortex is 
shown in the left column (A,D,G,J,M). Cell-type speciﬁ  c antibody labeling in 
the corresponding sections are shown in the middle column (B,E,H,K,N). 
Overlaps of the left and middle columns are shown in the right column – 
(C,F,I,L,O) – calretinin [CR – (B,C)], parvalbumin [PV – (E,F)], somatostatin 
[SST – (H,J)], vasoactive intestinal polypeptide [VIP – (K,L)] and neuropeptide Y 
[NPY – (N,O)]. Cells that have GFP label only are marked with green boxes. 
Cells that have cell-type speciﬁ  c antibody label only are marked with red boxes. 
Cells that are co-labeled are marked with yellow boxes. Dorsal (D) and lateral (L) 
directions for all images are as indicated in (O). The scale bar for all images, 
shown in (O), is 50 µm.Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  14
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SST inhibitory neuron populations; and of A930038C07Rik (AAV-
mA93) – based on characteristic inhibitory neuron expression pat-
terns observed in the Allen Mouse Brain Atlas (Lein et al., 2007) and 
targeting an unknown subpopulation of inhibitory neurons.
Next, we also used microarray data from somatosensory and 
cingulate cortices compiled by Sugino et al. (2006) to identify genes 
co-expressed within one of the inhibitory neuron subtypes G42 (PV), 
GIN (SST) or G30 (VIP), and not expressed in excitatory neurons. 
A detailed description of the rationale for choosing these genes and 
promoter design are provided in Material and Methods. First we 
analyzed the microarray data for genes that showed more than 3-fold 
enrichment for a single inhibitory neuron cell-type (see Table S1 in 
Supplementary Material). Because microarray data is prone to false 
positives, these genes were then checked in the Allen Mouse Brain 
Atlas (Lein et al., 2007) for a pattern of scattered expression, con-
sistent with inhibitory neuron distribution. For each selected gene, 
upstream and 5′ UTR gene regions were analyzed for the presence of 
putative TFBSs that were conserved across multiple mammalian spe-
cies. Conserved TFBSs enriched in a group of co-expressed genes were 
hypothesized to be determinant regulatory elements for a speciﬁ  c 
cell-type (see Tables S2–4 in Supplementary Material). In search of 
promoter sequences most likely to drive cell-type speciﬁ  c expression 
we chose the ones with the maximum number of cell-type speciﬁ  c 
regulatory elements and a minimum number of elements character-
istic of the other inhibitory cell-types. Using this strategy, AAV vectors 
expressing RFP were designed with regulatory elements derived from 
the human genes, aimed at targeting each of the three non-overlap-
ping interneuron cell-types: for SST cell-type – glutamate receptor, 
metabotropic 1 (AAV-hGRM1), c-type natriuretic peptide precursor 
(AAV-hNPPC); for PV cell-type – adrenomedullin (AAV-hADM), 
type 2 lactosamine alpha-2,3-sialyltransferase (AAV-hST3GAL6); 
for VIP cell-type – ras responsive element binding protein 1 (AAV-
hRREB1), deiodinase, iodothyronine, type II (AAV-hDIO2), nuclear 
receptor subfamily 2, group F, member 2 (AAV-hNR2F2).
Injections of viruses into the cortex of mice or rats revealed that 
only some of the mammalian promoters drove transgene expression 
(Table 2) and only AAV-mA93 showed some cell-type speciﬁ  city. 
Morphologies of cells labeled by LV-mGAD2, LV-mSST and AAV-
hPDGFRA indicated that these vectors expressed in some excitatory 
pyramidal neurons (Figures 10A–C). LV-mSST also drove expres-
sion in some glia (Figure 10B). AAV-hNPPC, AAV-hNR2F2 and 
AAV-hDIO2 failed to label any cells in mouse cortex. GAD67-GFP 
knock-in mice injected with viruses expressing RFP are shown in 
Figure 11. RFP+ cells that co-labeled with GFP were inhibitory. The 
sections were also stained with parvalbumin (PV) antibody. AAV-
hADM drove expression in only a few cells, all of which appeared 
to be glia (Figures 11A–D). Expression of AAV-hGRM1 (Figures 
11E–H), AAV-hRREB1 (Figures 11I–L) and AAV-hST3GAL6 
(Figures 11M–P) drove expression in both excitatory and inhibi-
tory neurons. In contrast, AAV-mA93 (Figures 11Q–T) did not 
appear to label any excitatory neurons, but strongly labeled inhibi-
tory neurons and glia. AAV-hGRM1, AAV-hRREB1, AAV-hST3GAL6 
and AAV-mA93 labeled inhibitory neurons that were PV+ and PV−, 
indicating that none of these promoters drove inhibitory neuron sub-
type speciﬁ  c expression. Interestingly, most of the PV+ cells labeled 
by AAV-hRREB1 displayed pyramidal morphology. Since some 
FIGURE 8 | Percentage of virus label in inhibitory neuron subtypes. Viruses 
expressing GFP were injected into mouse somatosensory cortex and stained 
for inhibitory neuron markers calretinin (CR), parvalbumin (PV), somatostatin 
(SST), vasoactive intestinal polypeptide (VIP) and neuropeptide Y (NPY). 
Percentages were calculated by dividing the number of co-labeled cells (GFP 
and cell-type speciﬁ  c antibody) by the total number of antibody labeled cells in 
the injected region. The percentages reﬂ  ect the combined labeling in cortical 
layers 2/3–6 and the standard deviations show the labeling distributions treating 
each section as an independent observation. Sections were counted from a 
single animal for AAV-fPV, and from three animals for all others. NPY label was 
not counted for AAV-fPV and AAV-fCR. At least 170 cells were counted for each 
vector/antibody combination (see Materials and Methods).Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  15
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 pyramidal cells have been shown to express low levels of PV protein 
in   monkey (Preuss and Kaas, 1996) and mRNA in mouse (Sugino 
et al., 2006), it is possible AAV-hRREB1 largely restricted expression 
to PV+ cell-types, both excitatory and inhibitory. Altogether, many 
of the mammalian promoters failed to express in the cortex, and 
those that drove expression did not appear to restrict expression to 
inhibitory neurons better than the fugu promoter sequences.
TRANSCRIPTION FACTOR BINDING SITE (TFBS) ASSEMBLED 
PROMOTERS
As an alternative strategy to drive cell-type speciﬁ  c expression in 
inhibitory neurons, we created artiﬁ  cial promoter constructs assem-
bled with known transcription factor binding sites DR1 (Okuno 
et al.,  2001) or E1.1 (Scardigli et  al., 2003). The PPARγ/RXRα 
( peroxisome-proliferator-activated receptor gamma/retinoid X recep-
tor alpha) transcription factor complex (Okuno et al., 2001) binds to 
the 24-bp DR1 motif. According to Sugino et al.’s (2006) microarray 
data, PPARγ is enriched in the PV+ population and RXRα is expressed 
at high levels in SST+ and VIP+ inhibitory populations, and at low 
levels in the PV+ population. Since PPARγ/RXRα complex binds to 
DR1 in the presence of high molar ratios of PPARγ to RXRα (Okuno 
et al., 2001), we expected positive activity of DR1 in PV+ cells.
The E1.1 enhancer element contains 11 nucleotides of the 16-nucle-
otide PAX6 consensus binding sequence and reportedly restricted 
expression in Ngn2 positive cells by binding PAX6 in the mouse spinal 
cord and telencephalon (Scardigli et al., 2003). Since Sugino et al.’s 
(2006) data suggested that PAX6 is enriched in the VIP+ inhibitory 
population, we expected positive activity of E1.1 in VIP+ cells.
FIGURE 9 | Fugu promoters in LV drove expression in large numbers of 
excitatory neurons. Fugu promoters in LV expressing GFP were injected into 
mouse somatosensory cortex – LV-fPV (A,B), LV-fSST (C,D), LV-fNPY (E), LV-fCR 
(F). Panels (B) and (D) are magniﬁ  ed versions of the boxed regions of (A) and 
(C), respectively. Arrows mark excitatory pyramidal neurons. Dorsal (D) and 
lateral (L) directions for all images are as indicated in (F). Scale bars are 50 µm.Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  16
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Table 2 | AAV and LV vectors with mammalian promoters.












Synapsin AAV-hSYN RFP 8.44E + 12 468 All neurons − +++ +++
Glutamate 
decarboxylase 2





AAV-mA93 RFP 1.21E + 11 2694 Inhibitory 
neurons
+++ − +++

















AAV-hNPPC RFP 2.64E + 12 2585 Inhibitory neuron 
subtype (SST)
NE NE NE
Adrenomedullin AAV-hADM RFP 2.41E + 12 2555 Inhibitory neuron 
subtype (PV)
+− −
Type 2 lactosamine 
alpha-2,3-
sialyltransferase
AAV-hST3GAL6 RFP 3.02E + 12 2739 Inhibitory neuron 
subtype (PV)




AAV-hRREB1 RFP 3.16E + 12 2715 Inhibitory neuron 
subtype (VIP)
−+ + + +
Deiodinase, 
iodothyronine, type II




subfamily 2, group F , 
member 2
AAV-hNR2F2 RFP 9.60E + 10 2568 Inhibitory neuron 
subtype (VIP)
NE NE NE
(a) Adeno-associated virus (AAV) and lentivirus (LV). Mouse and human derived sequences are denoted by the preﬁ  x “m” and “h” , respectively.
(b) Length of the promoter used in the virus (bases).
(c) Scoring is relative to other viruses. NE = no expression. ND = not determined.
(d) Scoring is generally from mouse injections. Rat scoring is indicated.
FIGURE 10 | Mammalian promoters drove expression in rodent cortex. 
Mice were injected with LV expressing GFP driven by mouse promoter 
sequences for glutamate decarboxylase 2 [LV-mGAD2 – (A)] and somatostatin 
[LV-mSST – (B)]. Rats were injected with AAV expressing GFP driven by the 
human promoter sequence for platelet-derived growth factor receptor, alpha 
polypeptide [AAV-hPDGFRA – (C)]. Rightward pointing arrows mark glia and 
leftward pointing arrows mark excitatory pyramidal neurons. Dorsal and lateral 
directions for all images are as indicated in (C). Scale bars are 50 µm.Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  17
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FIGURE 11 | Mammalian conserved TFBS promoters drove expression in 
mouse brain. GAD67-GFP knock-in mice were injected with AAV expressing 
RFP driven by promoter sequences with presumed cell-type speciﬁ  c regulatory 
elements. Images in each row are images of the same section. Green label in 
the ﬁ  rst column on the left (A,E,I,M,Q) is inhibitory neuron speciﬁ  c GAD67-GFP 
expression. Red label in the second column from the left (B,F,J,N,R) is RFP virus 
expression. Blue label in the third column from the left (C,G,K,O,S) is 
parvalbumin (PV) antibody label. The right column (D,H,L,P ,T) is the merge of the 
previous columns. Overlap of green and red is yellow; green and blue is teal; red 
and blue is purple; green, red and blue is white. Viral vectors were as follows: 
adrenomedullin [AAV-hADM – (A–D)], glutamate receptor, metabotropic 1 
[AAV-hGRM1 – (E–H)], ras responsive element binding protein 1 [AAV-hRREB1 – 
(I–L)], type 2 lactosamine alpha-2,3-sialyltransferase [AAV-hST3GAL6 – (M–P)] 
and riken gene A930038C07Rik [AAV-mA93 – (Q–T)]. Examples of double and 
triple labeled cells are marked with boxes. The color of the box matches the cell 
overlap color. Rightward pointing arrows mark glia and leftward pointing arrows 
mark excitatory pyramidal neurons. Dorsal (D) and lateral (L) directions for all 
images are as indicated in (T). Scale bars are 50 µm.Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  18
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The neuron restrictive silencing element (NRSE) is a 21- to 23-bp 
DNA transcription factor binding site found in many neuronal 
genes. The neuron restrictive silencing factor (NRSF) silences neu-
ronal genes in non-neuronal cells by binding to NRSE through the 
association of the histone deacetylase complex (Huang et al., 1999; 
Naruse et al., 1999) or methyl-CpG-binding protein 2 (Lunyak et al., 
2002). We expected the incorporation of this negative regulator of 
transcription to restrict promoter activity to neuronal cells.
Three composite regulatory element (CRE) promoters were 
created by combining DR1 or E1.1 motifs with or without NRSE 
and a minimal CMV promoter (see Table 3 and Materials and 
Methods). Mice and rats were injected with vectors expressing 
either GFP or RFP under the control of these CRE promoters. 
AAV-DR1-NRSE (RFP) expressed in only a few cells, most of 
which appeared to be glia (Figure 12). In contrast, AAV-E1.1 
and AAV-E1.1-NRSE expressed strongly and only in a handful of 
cells scattered over up to ∼200 µm from the injection. AAV-E1.1-
NRSE (RFP) expression is shown in Figure 13. We have observed 
other viral vectors driving expression at similarly far distances, 
but the density of cell expression for AAV-E1.1 and AAV-E1.1-
NRSE were sparse, suggesting that these promoters restricted 
  expression to only some cell-types. Most of the RFP labeled cells 
from AAV-E1.1-NRSE co-labeled with GAD67-GFP, indicating 
this vector predominantly drove expression in inhibitory neurons 
(Figures 13A–D,G,H), but a few glial cells also expressed RFP. 
While the addition of the NRSE to AAV-E1.1 appeared to reduce 
glia expression, probably the single copy of NRSE in AAV-E1.1-
NRSE was not sufﬁ  cient to completely restrict expression to neu-
rons. Notably, in mice very few RFP labeled cells co-labeled with 
parvalbumin (PV) antibody, and expression in these cells was faint 
(Figures 13E–H). Thus, in mice AAV-E1.1-NRSE largely restricted 
expression to non-parvalbumin inhibitory neurons. Interestingly 
however, when rats were injected with AAV-E1.1 (without NRSE), 
transgene co-labeled with antibodies to inhibitory neuron sub-
types (CR, SST and VIP), and PV (data not shown), suggesting 
that the PAX6 transcription factor may be expressed differently 
in inhibitory neurons of mouse and rat.
DISCUSSION
In this study we targeted inhibitory neuron subtype speciﬁ  c expres-
sion using promoter sequences in viral vectors. While none of the 
promoters tested were capable of restricting expression to  inhibitory 
Table 3 | AAV vectors with composite regulatory element (CRE) promoters.













binding site with 
NRSE










AAV-E1.1-NRSE RFP 1.53E + 12 239 Inhibitory neuron 
subtype (VIP)
+−+
(a) Adeno-associated virus (AAV).
(b) Length of the promoter used in the virus (bases).
(c) Scoring is generally from mouse injections. Rat scoring is indicated.
FIGURE 12 | AAV-DR1-NRSE drove expression in only a few cells. 
AAV driven by the composite regulatory element promoter containing 
DR1 and NRSE motifs (AAV-DR1-NRSE) was injected into mouse 
somatosensory cortex. Expression of the RFP AAV transgene is shown 
in red (A) and PV antibody staining in blue (B). Overlap of red and blue 
images is shown in (C). Glia are marked with arrows. Dorsal (D) and 
lateral (L) directions for all images are as indicated in (C). Scale bars are 
50 µm.Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  19
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FIGURE 13 | AAV-E1.1-NRSE drove strong expression in a scattered 
population of cells. AAV with a promoter containing the E1.1 and NRSE motifs 
(AAV-E1.1-NRSE) was injected into the somatosensory cortex of GAD67-GFP 
knock-in mice (A,B,G,H). Expression of the RFP AAV transgene is shown in red 
(C,D,G,H) and parvalbumin (PV) antibody staining in blue (E–H). Green and red is 
yellow. The color of the box matches the cell overlap color. Glia are marked with 
arrows. Dorsal (D) and lateral (L) directions for all images are as indicated in (H). 
Scale bars are 50 µm.Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  20
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neuron subtypes, AAV-fSST largely restricted expression to  inhibitory 
neurons both in mouse and in rat. Therefore the SST fugu promoter 
might be a useful vector in rodent studies targeting the inhibitory 
neuron class as a whole. In addition, the expression shown by the 
artiﬁ  cial promoter construct AAV-E1.1-NRSE demonstrates that 
this vector might be useful for studies targeting SST and VIP, but 
not PV immunoreactive inhibitory neurons in mice.
In the search for inhibitory neuron speciﬁ  c promoters, we showed 
that rAAV2/1 is a suitable vector for testing promoter sequences in 
mouse cortex. Label from AAV-hSYN (and also the fugu vectors in 
AAV), overlapped with the classical inhibitory neuron markers CR, 
NPY, SST, PV and VIP. While nearly all of the NPY, and the majority 
of CR, SST and PV immunoreactive cells were labeled using high 
titer rAAV2/1, only about half of the VIP immunoreactive cells 
were labeled. Since we previously observed that labeling efﬁ  ciency 
of rAAV2/1 can be biased towards inhibitory neurons depending on 
the titer of the virus (Nathanson et al., 2009), we might also suspect 
that lower titers of virus could result in even fewer proportions of 
VIP labeled cells. Therefore, one must be cautious in interpreting 
quantitative results of promoter activity of AAV vectors in inhibi-
tory neurons. This caution is relevant to all viral vectors, and viral 
tropism should be considered by ﬁ  rst using promoters capable of 
driving the most ubiquitous expression.
In this study we showed that all of the fugu promoters tested 
drove expression in the mammalian brain. Some of the tested 
fugu promoter sequences largely restrict expression to inhibi-
tory GABAergic neurons (fSST and fNPY); some promoters limit 
expression to neuronal cells in general; and others drive expresson 
in glia as well. None restricted expression to inhibitory neuron sub-
types. One possibility for the lack of speciﬁ  city is that the tested fugu 
sequences lack negative regulatory signals which might be located 
in sequences further 5′ of the cloned region, in 5′ UTRs, in introns, 
or in 3′ intergenic regions of the genes of interest. Alternatively, it 
is possible that inhibitory neuron cell-type speciﬁ  c gene expression 
cannot easily be duplicated in adult cells due to epigenetic changes 
such as CpG methylation. Also, the fact that none of the fugu pro-
moters restricted expression to a particular cell-type may suggest 
that the intricacies of inhibitory cell-type speciﬁ  c regulation may 
not be highly conserved among ﬁ  sh and mammals. Indeed, recent 
work has shown that inhibitory neuron expression can differ even 
between the small evolutionary distances between different rodent 
species. Xu et al. (2006) has shown that unlike in rat, CR expresses 
in a subset of SST+ cells in mice which are otherwise similar across 
species in both morphology and intrinsic physiology. Since even 
simple base pair substitutions and changes in distances between 
regulatory elements can change gene expression (Rodriguez-
Trelles et al., 2003), complex regulatory environments involving 
many interacting factors may not be commonly shared between 
evolutionarily distant species. Small genetic differences can have 
a profound effect if the regions of difference are important. King 
and Wilson (1975), among others, have suggested that the profound 
phenotypic differences between humans and chimpanzees which 
share more than 98.5% nucleotide identity (Ebersberger et al., 
2002), are likely a result of differences in the regulatory regions 
of genes. Indeed, ∼15% of CpG sites differ between human and 
chimpanzee (Ebersberger et al., 2002). Therefore, the ability for 
the same regulatory region to function across multiple species 
may be more a rarity than a rule, and those that are evolutionarily 
conserved are likely to be concentrated among genes that are devel-
opmentally indispensable. Indeed, the majority of evolutionarily 
conserved sequences between fugu and mammals have been found 
in the proximity of genes encoding transcription factors and/or 
genes expressed in early developmental stages (Woolfe et al., 2005). 
Regulation of the selected genes in inhibitory neuron subtypes may 
not have these evolutionary constraints. For example, expression 
of one calcium binding protein such as PV, might be replaced by 
another, such as calbindin.
As described, a collection of promoters drove expression in neu-
rons, but not glia (fSST, fNPY, fPV, fCAMK, hPDGRFA, hGRM1, 
hST3GAL6, hRREB1). Likewise, a set of the promoters preferen-
tially drove expression in inhibitory neurons with minimal exci-
tatory neuron expression (fNPY, fSST, mA93, E1.1-NRSE). These 
results suggest that the regulatory mechanisms responsible for 
driving expression in the broader cell-type classes of inhibitory 
neurons, excitatory neurons or glia, may be relatively simple and 
shared between species. Nevertheless, identiﬁ  cation of these regula-
tory mechanisms between inhibitory and excitatory neurons has 
remained elusive. In contrast to inhibitory neurons as a whole, our 
inability to achieve subtype speciﬁ  c expression in inhibitory neu-
rons suggests subtype regulatory mechanisms are quite complex. 
To this point, even the simple E1.1-NRSE composite regulatory 
element drove expression in multiple inhibitory neuron subtypes. 
These results suggest that complex regulatory environments includ-
ing antagonistic repressors may be needed to restrict expression to 
inhibitory neuron subtypes.
Lentiviral vectors containing fCR, fSST, fNPY and fPV promot-
ers were also tested. These promoters were larger than in AAV, 
encompassing the promoters tested in AAV, and in some cases 
including the entire 5′ intergenic region. We consistently observed 
many more excitatory neurons in LV than in AAV injected brains 
among corresponding promoters. In a previous study (Nathanson 
et al., 2009) we demonstrated that AAV preferentially drove expres-
sion in inhibitory neurons relative to excitatory neurons. With this 
understanding, the consistent expression differences between cor-
responding promoters in our current study supports the possibility 
that viral vector tropism might have contributed more to increased 
LV excitatory neuron expression than did the differences in compo-
sition between the corresponding AAV and LV promoter versions. 
Nevertheless, AAV-fCR drove expression in glia while LV-fCR did 
not. Since both AAV and LV efﬁ  ciently transduce glia, these results 
suggest differences in the content of these promoters were respon-
sible for these observed differences in glia expression.
None of the mammalian promoters taken from the group of co-
expressed genes showed inhibitory neuron speciﬁ  city. The computa-
tional analysis did not resolve the necessary elements for inhibitory 
neuron cell type speciﬁ  city. Yet, we might have improved inhibitory 
versus excitatory neuron speciﬁ  city if we had contrasted promoter 
sequences from the inhibitory neuron cell-type groups with those 
of excitatory neurons, rather than just between inhibitory neuron 
cell-type groups. In addition, one major limitation towards achiev-
ing inhibitory neuron cell-type speciﬁ  c regulation was the relatively 
small number of genes for which we could reasonably presume to 
be co-expressed in each of the cell-type groups. Also, the variability 
of genes within each inhibitory neuron subtype cluster, as evident Frontiers in Neural Circuits  www.frontiersin.org  November 2009  | Volume 3  |  Article 19  |  21
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by the different patterns of expression seen in various regions of 
the mouse brain, indicate that many of the co-expressed genes are 
not associated or co-regulated in the same cell-types outside of 
cortex. Given these limitations, it was not entirely unexpected that 
we did not ﬁ  nd TFBSs which were strongly enriched in one cell-
type and absent from the others. Rather than searching for deter-
minant cell-type speciﬁ  c factors, we were resolved to ﬁ  nd factors 
largely enriched in a group. To this end, the analysis revolved around 
establishing ratios that were out of balance between cell-types (see 
Tables S2–4 in Supplementary Material). If however our dataset 
truly consisted of co-expressed genes and the regulatory environ-
ments were not too complex, we might expect that an analysis of 
a limited and noisy dataset could succeed in identifying common 
regulatory elements. However, together with the lack of cell-type 
speciﬁ  city of the fugu promoters, these results suggest that regula-
tion of inhibitory neuron cell-type speciﬁ  city is likely complex and 
might also involve epigenetic regulation.
How well does the clustering of co-expressed genes reﬂ  ect co-
regulation? Since a microarray snapshot identifying the groups of 
co-expressed genes does not account for the dynamically responsive 
nature of regulatory elements, it may be useful to obtain lists of 
co-expressed genes satisfying multiple discriminating criteria. For 
example, do the genes (1) change together under various conditions 
(Luscombe et al., 2004); (2) share common biological pathways 
(Okuda et al., 2006); and/or (3) show consistent anatomical expres-
sion in more than one brain structure? One possible combination 
using existing data for ﬁ  nding inhibitory subtype speciﬁ  c regulatory 
elements, would be to combine Sugino et al.’s (2006) microarray 
dataset with a complete survey of the Allen Mouse Brain Atlas 
(Lein et al., 2007). Inhibitory neurons show distinct patterns of 
expression throughout the brain, including the cerebellum, cortex, 
hippocampus and reticular thalamus. Therefore, genes that share 
common patterns of expression in many regions, and are found 
by microarray data to be enriched in a speciﬁ  c cell-type, could 
provide a more stringent and larger basis for identifying common 
regulatory elements.
Composite regulatory element (CRE) promoters appear to 
present a viable option for creating cell-type speciﬁ  c promoters. 
Indeed, of all of the promoters tested, the AAV-E1.1-NRSE vector 
showed the most potential for inhibitory neuron subtype selectivity. 
In addition, the simplicity of this promoter suggests that relatively 
simple modiﬁ  cations might also yield signiﬁ  cant improvements. 
For example, further reduction in glial expression might be 
achieved by adding additional NRSE sites. And since Bessis et al. 
(1997) has shown that the distance between NRSE and other factors 
can affect whether the NRSF/NRSE restricts or enhances activ-
ity, the suppression activity of the NRSE sites might be enhanced 
by increasing the distance between the NRSE sites and the other 
binding sites in the CRE. One option for increasing the activity of 
the AAV-DR1-NRSE vector might be to add multiple copies of the 
DR1 motif as is the case in the E1.1 vectors. Alternatively, since the 
Pal3 motif (Okuno et al., 2001) can bind the PPARγ homodimer 
without RXRα, this element may prove to drive stronger expres-
sion in PV+ cells. Despite the apparent simplicity of these vectors, 
the number and arrangement of factors in precise orders and at 
speciﬁ  c distances, consistent with the natural placements, might 
be important for correct regulation. Therefore the usefulness of 
regulatory elements as building blocks for obtaining speciﬁ  c and 
complex regulation may require extensive characterization of these 
elements. Given the selectivity of the AAV-E1.1-NRSE vector, the 
extremely short promoter sequences, and that expression datasets 
such as the microarray dataset by Sugino et al. (2006) can identify 
candidate transcription factors, the CRE approach may be a ripe 
strategy in the pursuit of cell-type speciﬁ  c promoters.
Neither of our promoter approaches achieved inhibitory neu-
ron cell-type speciﬁ  city. It is possible that there are few work-
able solutions for inhibitory neuron cell-type promoters given 
promoter complexities and the size limitations in AAV and LV. 
At this point, the only dependable method for transcriptional 
targeting of speciﬁ  c cell populations using inserted DNA is with 
large BAC sequences, which are used for the creation of transgenic 
animals (Heintz, 2001). One possible viral vector based alternative 
to AAV or LV may be the use of HSV vectors, which can incor-
porate BACs of up to 150 kb (Saeki et al., 1998). Efforts to make 
HSV suitable for gene therapy applications are ongoing (Berges 
et al., 2007), and may prove the best suited vector when cell-type 
speciﬁ  c control is desired. Alternatively, viral pseudotyping via cap-
sid modiﬁ  cations may be a useful approach for cell-type speciﬁ  c 
targeting (Choi et al., 2005). Where smaller regulatory elements 
are required, multi-faceted approaches, including multi-pronged 
bioinformatic comparisons of co-expressed genes and composite 
regulatory element promoters are perhaps the most promising 
avenues of pursuit, and may yield new insights towards achieving 
cell-type speciﬁ  c regulation.
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